New CV data to add to alogliptin's safety allure?
This article was originally published in Scrip
New subanalyses of findings from the large-scale EXAMINE outcomes study with Takeda's antidiabetic alogliptin have added to the cardiovascular safety profile of the DPP-4 inhibitor in patients at high cardiovascular risk and may help differentiate the product in a crowded segment.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.